Oxaliplatine Fresenius Kabi

Oxaliplatin, the active ingredient in Oxaliplatine Fresenius Kabi, is a platinum-based chemotherapy agent presented as a sterile solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Oxaliplatine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oxaliplatin is used primarily for colorectal cancer treatment pathways and the following clinical applications: - Metastatic colorectal cancer: Provides clinical benefit by reducing tumour growth. - Adjuvant therapy for stage III colon cancer: Reduces recurrence risk after surgical resection. - Combination regimens (e.g., FOLFOX): Enhances overall response rates when combined with 5‑fluorouracil and leucovorin. - Gastro‑gastrointestinal tumours including gastric and esophageal cancers : Offers additional treatment options in multimodal approaches. - Peritoneal carcinomatosis of colorectal origin : Used in regional perfusion techniques for local control of disease. - Rare treatment ‑ off‑label use for pan‑    …  …  …  … … … … … … … … … … …

The          …  …  …  …